Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

Research could lead to new drug treatment for metabolic diseases

A team of Harvard School of Public Health (HSPH) scientists report finding a molecular "switch" that can "turn off" some cellular processes that are protective against aging and metabolic diseases. While more research is needed, the findings may open doors for new drug treatments to halt or slow development of metabolic diseases like type 2 diabetes or heart disease. The research findings appear in the December 1, 2010 issue of Cell Metabolism.

1 Dec 2010

New tool helps gauge care for people with neurological disorder

A national conversation continues about the best ways to improve both the quality of medical care and to contain costs. So far, developing quality measurements has focused on primary care or highly prevalent, chronic conditions such as asthma and diabetes. But what about brain disorders? To date, the number of measures that apply to neurologic care has been limited.

1 Dec 2010

New brain imaging technique can trace effects of SYN115 drug in Parkinson's disease

Neuroscientists using a new brain imaging technique could see an investigational drug for Parkinson's disease get into a patient's brain and affect blood flow in several key structures, an indicator the drug may be effective.

1 Dec 2010

Neuraltus reports positive results from NP001 Phase 1 study for ALS

Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet medical needs, primarily for the treatment of neurodegenerative diseases, announced today top-line results from the Company's Phase 1 clinical study of NP001 for the treatment of Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease).

30 Nov 2010

New tool helps doctors gauge how well they care for people with Parkinson's disease

The American Academy of Neurology has developed a new tool to help doctors gauge how well they are caring for people with Parkinson's disease. The new quality measures are published in the November 30, 2010, issue of Neurology®, the medical journal of the American Academy of Neurology.

30 Nov 2010

Breastfeeding while remaining on epilepsy medications may not affect child's IQ

There's good news for women with epilepsy. Breastfeeding your baby while taking your seizure medication may have no harmful effect on your child's IQ later on, according to a study published in the November 24, 2010, online issue of Neurology-, the medical journal of the American Academy of Neurology.

25 Nov 2010

Hepcidin hormone may be potential therapeutic tool for anemic blood disorders

A hormone made by the body may be a potential therapeutic tool for the treatment of two anemic blood disorders beta-thalassemia and hemochromatosis. The new research was led by scientists at Weill Cornell Medical College and published in the Journal of Clinical Investigation and the journal Blood.

24 Nov 2010

XenoPort receives grant from Michael J. Fox Foundation to support Parkinson's disease therapies

XenoPort, Inc. announced today that it has been awarded a grant from The Michael J. Fox Foundation for Parkinson's Research to support a preclinical study of the efficacy and safety of a novel, orally administered prodrug of acamprosate in reducing L-Dopa induced dyskinesias (LID) in a pre-clinical model of Parkinson's disease.

24 Nov 2010

Parkinson Society Canada awards Quebec scientists $573,384 for research

Quebec Parkinson researchers receive a record $573,384 in funding from Parkinson Society Canada to increase their efforts to identify the causes of this degenerative brain disease for which there is currently no cure. At a Research Innovation event in Montreal this evening, hosted by Parkinson Society Quebec in partnership with McGill University and the CHUM, 11 Parkinson scientists will be lauded for their efforts in getting closer to a cure.

23 Nov 2010

Rate, direction of axon growth in spinal cord can be controlled, study shows

Both the rate and direction of axon growth in the spinal cord can be controlled, according to new research by USC College's Samantha Butler and her collaborators.

23 Nov 2010

Lotsa Helping Hands' new feature connects community members to healthcare nonprofit organizations

Lotsa Helping Hands, the leading provider of a web-based caregiving coordination service, today announces a new feature that connects its community members to trusted resources from many of the nation's leading healthcare nonprofit organizations.

20 Nov 2010

Ontario Brain Institute initiates new venture to help people with neurological disorders

Ontario took a major step to help the one million people in the province with neurological disorders and the 2.6 million Ontarians who will be affected by a neurological condition in their lifetime.

20 Nov 2010

NexACT technology improves oral delivery of five small molecule drugs

Apricus Biosciences, Inc., today announced data from animal studies showing that the NexACT technology significantly improved the oral delivery of five small molecule drugs tested, with the best improvements up to 20-fold, in terms of improvement in absorption.

20 Nov 2010

FDA clears Multi-Lead Trialing Cable for SCS therapy

Medtronic Inc., the leader in spinal cord stimulation for more than 25 years, today announced U.S. Food and Drug Administration (FDA) clearance and the global launch of the Multi-Lead Trialing Cable for use in the patient screening test for Medtronic spinal cord stimulation (SCS) therapy.

19 Nov 2010

Impax announces positive top-line results of Phase III IPX066 study for Parkinson's disease

Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc., today announced positive top-line results of the APEX-PD Phase III clinical study with IPX066 in Parkinson's disease (PD). IPX066 is a novel extended release carbidopa-levodopa product.

19 Nov 2010

Pericyte cells become key players in shaping blood flow in the brain

Cells in the brain called pericytes that have not been high on the list of targets for treating diseases like Alzheimer's may play a more crucial role in the development of neurodegenerative diseases than has been realized.

18 Nov 2010

Anti-cancer drug smuggled using a nanocarrier past protective blood-brain barrier into brain tumours

Scientists in Germany have developed a way of smuggling an anti-cancer drug past the protective blood-brain barrier and into brain tumours and metastases using a nanocarrier - a tiny capsule specially designed to pass through cell membranes and deliver its anti-cancer drug to the cancer cell.

18 Nov 2010

Cigarette smoke, automobile exhaust and french fries increase risk of developing Alzheimer's disease

There is growing evidence that exposure to a group of chemicals known as type-2 alkenes -- which are found in the smoke inhaled from cigarettes, the exhaust of automobiles and even in French fries - can increase the chances of developing Alzheimer's disease and other neurological conditions such as Parkinson's disease.

18 Nov 2010

Amsterdam 2010 third quarter total expense increases from EUR 4.4 million to EUR 4.7 million

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today provides its non-audited business update in compliance with the EU transparency directive. This report summarizes material events and AMT's financial position for the third quarter of 2010.

18 Nov 2010

Sangamo presents Phase 2 clinical data in ALS at Society for Neuroscience Meeting

Sangamo BioSciences, Inc. announced today the presentation of Phase 2 clinical data from its ZFP Therapeutic program to develop SB-509, a zinc finger protein transcriptional activator (ZFP-TF) of the vascular endothelial growth factor (VEGF)-A gene as a treatment for ALS.

17 Nov 2010

Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

Research could lead to new drug treatment for metabolic diseases

New tool helps gauge care for people with neurological disorder

New brain imaging technique can trace effects of SYN115 drug in Parkinson's disease

Neuraltus reports positive results from NP001 Phase 1 study for ALS

New tool helps doctors gauge how well they care for people with Parkinson's disease

Breastfeeding while remaining on epilepsy medications may not affect child's IQ

Hepcidin hormone may be potential therapeutic tool for anemic blood disorders

XenoPort receives grant from Michael J. Fox Foundation to support Parkinson's disease therapies

Parkinson Society Canada awards Quebec scientists $573,384 for research

Rate, direction of axon growth in spinal cord can be controlled, study shows

Lotsa Helping Hands' new feature connects community members to healthcare nonprofit organizations

Ontario Brain Institute initiates new venture to help people with neurological disorders

NexACT technology improves oral delivery of five small molecule drugs

FDA clears Multi-Lead Trialing Cable for SCS therapy

Impax announces positive top-line results of Phase III IPX066 study for Parkinson's disease

Pericyte cells become key players in shaping blood flow in the brain

Anti-cancer drug smuggled using a nanocarrier past protective blood-brain barrier into brain tumours

Cigarette smoke, automobile exhaust and french fries increase risk of developing Alzheimer's disease

Amsterdam 2010 third quarter total expense increases from EUR 4.4 million to EUR 4.7 million

Sangamo presents Phase 2 clinical data in ALS at Society for Neuroscience Meeting

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in